Abstract: Provided herein are methods to promote tissue healing, to treat tissue injury or to treat a condition related to tissue injury comprising administering to a subject in need thereof an effective amount of one or both of: a CAMKK1 polypeptide or an equivalent thereof; or an SDF-1 polypeptide or an equivalent thereof, in the presence of CXCR4 polypeptide expression, wherein the effective amount is an amount that induces exosome production, secretion and/or function in the subject. Recombinant stem cells are also provided that overexpress one or both of a CAMKK1 protein or polypeptide and/or an SDF-1 protein or polypeptides. The stem cells and products produced from them are useful to treat ischemic or inflammatory conditions as well as to promote tissue healing.

Abstract: Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metabolic disturbances. The present invention provides methods for treating erectile dysfunction in a male subject comprising administering to the major pelvic ganglion supplying the cavernous nerves subject compositions comprising SDF-1. SDF-1 promotes stem cell activation, to the major pelvic ganglion supplying the cavernous nerves, helps cell preservation, and prevents adverse penile remodeling. It can be administered as a protein or by gene therapy including but not limited to plasmid DNA, viral transduction, or nanoparticle delivery directly to the penis or to the neurovascular bundle or other pelvic nerve structures during the time of surgery, or before injury, or to treat existing erectile dysfunction.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: Provided herein are methods to promote tissue healing, to treat tissue injury or to treat a condition related to tissue injury comprising administering to a subject in need thereof an effective amount of one or both of: a CAMKK1 polypeptide or an equivalent thereof; or an SDF-1 polypeptide or an equivalent thereof, in the presence of CXCR4 polypeptide expression, wherein the effective amount is an amount that induces exosome production, secretion and/or function in the subject. Recombinant stem cells are also provided that overexpress one or both of a CAMKK1 protein or polypeptide and/or an SDF-1 protein or polypeptides. The stem cells and products produced from them are useful to treat ischemic or inflammatory conditions as well as to promote tissue healing.

Abstract: A sump port drain adapter apparatus is disclosed which provides a small, lightweight vessel to capture and collect gastric reflux or stomach contents exiting the smaller lumen, or sump line, of a double lumen nasogastric tube while providing airflow to the sump line to prevent the nasogastric tube from adhering to the stomach lining. The apparatus disclosed prevents clogging in the sump line, unnecessary patient gown and bedding changes, patient skin breakdown and decreases exposure to potentially infectious material for both the patient and healthcare workers.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: In one embodiment, a pelvic visceral manipulator interface for use by the graspable tip of a robotic surgical system is disclosed. This interface can be used with any robotic pelvic medical procedure that utilizes manipulation of the uterus, vagina and/or colon. In one embodiment an interface aligns a robotic grasper arm with a visceral (uterine or vaginal/colon) manipulator for robotic laparoscopic pelvic surgery or pelvic medical procedure. In another embodiment, a manipulator includes an integrated tip for direct connection with the graspable tip of a robotic surgical system. In another embodiment, a robotic surgical arm includes an integrated tip for direct connection with a manipulator.

Abstract: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Abstract: Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K.

Abstract: A method for tracking an associated patient's progression through rehabilitation includes providing a database, providing a graphic user interface, establishing a functional work capacity for the associated patient, determining a workload based on the functional work capacity, acquiring data from the associated patients' rehabilitation exercises, entering the data into the database, creating a graphical representation of the data, and comparing the data with the workload.

Abstract: The combination of compounds of the hydroxytolan family with ascorbate plus naphthoquinone (Vitamin K3; VK3), or a quinone or semiquinone analogue of VK3, kill tumor cells, inhibit tumor growth and development, and treat cancer in subjects in need thereof.

Abstract: Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of “MgVC2”) and Vitamin K3 or (VK3) or a quinone and semiquinone analogue of VK3, are used in methods for killing or inhibiting the growth of tumor or cancer cells or preneoplastic cells in a subject, or for treating cancer in a subject in need of such treatment.

Abstract: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Abstract: A method and system of transforming patient care including a multi-disciplinary strategy consisting of the adoption of a “code” alert used to mobilize and coordinate all treatment caregivers, improve regional paramedic education, and a database to track the progress of a patient as they move through the emergency medical system is described. In an effort to reduce the elapsed time from when the patient first encounters medical providers to the time of treatment, the time intervals during a patient's treatment travel are tracked and analyzed to highlight areas that need to be improved upon.

Abstract: A pharmaceutical composition useful in the prevention of subconjunctival scarring that may occur after GFS comprising an effective amount of an ALK-5 inhibitor. Also disclosed is a method of treating disorder or condition of other ocular scarring or fibrosis including corneal haze and PVR that may develop after ocular surgery or injury comprising applying an amount of a pharmaceutical composition including an ALK-5 inhibitor to a post-surgical or injury site.

Abstract: Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of “MgVC2”) and Vitamin K3 or (VK3) or a quinone and semiquinone analogue of VK3, are used in methods for killing or inhibiting the growth of tumor or cancer cells or preneoplastic cells in a subject, or for treating cancer in a subject in need of such treatment.

Abstract: A method for tracking an associated patient's progression through rehabilitation includes providing a database, providing a graphic user interface, establishing a functional work capacity for the associated patient, determining a workload based on the functional work capacity, acquiring data from the associated patients' rehabilitation exercises, entering the data into the database, creating a graphical representation of the data, and comparing the data with the workload.

Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for an ovarian cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.